全球癌症疫苗市场：趋势、预测与竞争分析（~2030 年）

预计2030年，全球癌症疫苗市场规模将达到155亿美元，2024年至2030年复合年增长率为10.5%。该市场的主要驱动因素包括对更有效、侵入性更小的癌症治疗的需求不断增长、人们对癌症疫苗益处的认识不断提高以及政府促进癌症疫苗接种的支持措施。全球癌症疫苗市场前景广阔，医院和政府供应管道充满机会。

• 由于其在预防癌症发作方面的预防作用，预计预防市场在预测期内将出现最高增长。
• 在这个市场中，由于在医院接受癌症诊断和治疗的人数不断增加，医院在预测期内预计将出现高速成长。
• 由于癌症患者数量不断增加以及该地区医疗保健系统的建立，预计北美地区在预测期内将出现最高的增长。

癌症疫苗市场新趋势

癌症疫苗市场的新兴趋势正在塑造癌症治疗和预防的未来。这些趋势集中在技术进步、个人化医疗以及影响疫苗开发和采用的市场动态。

• mRNA 技术的进步：针对多种癌症的 mRNA 疫苗正在开发中，为个人化治疗和标靶免疫反应提供了潜力，带来创新和有效的癌症治疗。
• 个人化癌症疫苗：针对个人独特癌症特征量身订製的个人化癌症疫苗越来越受欢迎。这些疫苗旨在透过针对特定肿瘤抗原来刺激免疫系统，以提高疗效并减少副作用，代表着向更客製化和更有效的癌症治疗的转变。
• 人工智慧的整合：人工智慧（AI）越来越多地融入癌症疫苗的开发中。人工智慧演算法用于识别潜在的癌症标靶、优化疫苗设计并分析临床试验资料，加快开发进程并提高疫苗疗法的准确性。
• 增加对免疫肿瘤学的投资：对免疫肿瘤学的投资增加，其重点是开发利用人体免疫系统来对抗癌症的疫苗。这一趋势是由突破性治疗方法的潜力以及对癌症治疗中免疫系统机制的日益了解所推动的。
• 全球合作和伙伴关係：生物技术公司、学术机构和研究机构之间日益加强的全球合作和伙伴关係正在促进癌症疫苗的开发。这些合作促进了知识、资源和技术的共用，从而推动疫苗研究的进步并加速创新。

mRNA 技术的进步、个人化癌症疫苗、人工智慧的整合、免疫肿瘤学投资的增加以及全球研究合作等新兴全球趋势正在重塑癌症疫苗市场。这些趋势正在推动创新、提高精确度并改善治疗结果，从而带来更有效和个人化的癌症治疗。

癌症疫苗市场的最新趋势

癌症疫苗市场的最新趋势反映了研究、技术和监管支援的重大进展。这些发展正在促进提高疫苗的功效、个人化和可及性。

• 基于 mRNA 的癌症疫苗的开发：基于 mRNA 的癌症疫苗的开发是一项重大进展。这些疫苗利用 mRNA 平台编码癌症特异性抗原并引发有针对性的免疫反应。早期临床试验的成功以及 mRNA 技术在 COVID-19 疫苗中的应用正在加速该领域的进展。
• 新的治疗性癌症疫苗的核准：新的治疗性癌症疫苗的核准正在扩大治疗选择。最近监管部门核准了针对黑色素瘤和前列腺癌等疾病的疫苗，这为创新治疗方法和更广泛的临床应用铺平了道路。
• 临床试验扩大：癌症疫苗临床试验大幅扩大，参与国际合作试验增加。这项扩展可以对疫苗的功效和安全性进行更全面的测试，并加速开发针对多种癌症的新的和改进的疫苗。
• 联合治疗的出现：癌症疫苗与查核点抑制剂和标靶治疗治疗等其他治疗方法的联合治疗是一个显着的发展。将疫苗与其他治疗方法结合可以提高治疗效果，并提供治疗复杂癌症的新方法。
• 关注全球可及性和可负担性：提高癌症疫苗全球可近性和可负担性的努力正在取得进展。低收入和中等收入国家降低生产成本和增加疫苗供应的努力正在解决差异并加强全球癌症预防工作。

最近的趋势，例如基于 mRNA 的疫苗的进展、新治疗疫苗的核准、临床试验的扩大、联合治疗的出现以及对全球可及性的重视，正在对癌症疫苗市场产生重大影响。这些措施将促进创新、改善治疗选择并增加癌症治疗的机会。

癌症疫苗市场的策略性成长机会

在技​​术、研究和全球医疗保健需求进步的推动下，癌症疫苗市场的策略性成长机会在各种应用中不断出现。这些机会为扩大市场范围和增强治疗选择指明了道路。

• 扩大个人化疫苗：扩大个人化癌症疫苗的开发代表着一个重大的成长机会。透过根据个别患者情况和肿瘤特征量身定制疫苗，这种方法提供了更有效的治疗和改善患者预后的潜力。
• mRNA 和 DNA 疫苗技术的进步：mRNA 和 DNA 疫苗技术的进步为开发标靶癌症治疗方法提供创新平台，创造了成长机会。这些技术使得能够製造特异性针对癌细胞的疫苗，从而提供新的治疗可能性。
• 联合治疗的整合：癌症疫苗与免疫查核点抑制剂和标靶治疗治疗等其他治疗方法的整合带来了成长机会。联合治疗可以提高治疗效果并针对多种癌症类型，改善患者的治疗效果并扩大市场潜力。
• 关注全球市场渗透率：亚太和拉丁美洲等新兴地区市场渗透率的提高是一个成长机会。透过满足当地的医疗保健需求和增加疫苗的可及性，公司可以开拓新市场并加强其全球影响力。
• 投资研究合作：投资与学术机构和生技公司的研究合作和伙伴关係可提供成长机会。这些合作将加速尖端疫苗技术的开发，并加速新癌症治疗的进展。

癌症疫苗市场的策略性成长机会包括个人化疫苗的扩张、mRNA和DNA技术的进步、联合治疗的整合、专注于全球市场渗透以及合作研究的投资。这些机会将促进创新、增强治疗选择并扩大癌症治疗的市场范围。

癌症疫苗市场推广因素及挑战

癌症疫苗市场受到各种市场驱动因素和挑战的影响，包括技术进步、监管因素和经济考量。了解这些因素对于驾驭市场和推动成长至关重要。

推动癌症疫苗市场的因素包括：

1.技术进步：mRNA疫苗和DNA疫苗平台等技术创新使标靶和个人化癌症治疗的开发成为可能，推动市场成长。这些创新将提高疫苗功效并扩大治疗选择。

2.增加研究投入：增加癌症疫苗研究的投入将支持新型有效疫苗的开发。来自政府机构、私人投资者和製药公司的资金将加速研究并促进疫苗创新。

3. 意识和需求的提高：癌症预防和早期检测意识的提高将推动对癌症疫苗的需求。大众和专业人士对疫苗接种益处的认识将有助于增加市场采用和投资。

4. 监管支持和核准：创新癌症疫苗的监管支持和简化的核准流程将促进其进入市场。快速核准和支持性法律规范使新治疗方法能够快速开发和上市。

5. 合作研究计画：学术界、工业界和研究机构之间的合作研究倡议促进癌症疫苗开发的创新和进步。伙伴关係关係促进知识共用、资源分配和技术进步。

癌症疫苗市场面临的挑战包括：

1. 开发成本高：癌症疫苗研究和临床试验的开发成本高是一个问题。平衡成本、负担能力和市场潜力对于新疫苗的成功商业化至关重要。

2. 监管和合规复杂性：应对复杂的监管要求和合规问题是一项挑战。确保遵守不同的地区法规增加了疫苗开发和市场准入的复杂性。

3.市场进入和分配问题： 市场准入和分配挑战：市场准入和分配挑战，特别是在低收入和中等收入国家，影响癌症疫苗的供应和价格。解决这些问题对于扩大全球影响力和改善准入至关重要。

癌症疫苗市场的关键驱动因素包括技术进步、研究投资增加、意识和需求不断提高、监管支持和合作研究措施。主要挑战包括高昂的开发成本、监管复杂性和市场进入问题。解决这些因素对于促进癌症疫苗市场的成长和创新至关重要。

癌症疫苗按市场

该研究按疫苗类型、技术、分销管道和地区对全球癌症疫苗进行了预测。

国家癌症疫苗市场前景

癌症疫苗市场的最新发展是由技术创新、研究投资增加和癌症预防意识不断增强所推动的。美国、中国、德国、印度和日本取得了重大进展，反映出他们致力于透过疫苗开发改善癌症治疗和预防策略。

• 美国：在美国，随着个人化和治疗性疫苗开发的进展，癌症疫苗市场正在经历显着成长。最近的趋势包括开发针对多种癌症（如黑色素瘤和肺癌）的基于 mRNA 的疫苗。 FDA 加快了几种创新癌症疫苗的核准，支持更广泛的临床试验，并促进更快地获得新疗法。
• 中国：中国正在癌症疫苗市场快速推进，加大对生物技术和临床研究的投资。最近的趋势包括多种国产癌症疫苗的临床试验，重点是肝细胞癌和其他常见癌症的治疗方法。中国有利的法规环境和不断提高的研究能力正在促进创新并加速新型癌症疫苗的开发。
• 德国：德国仍然是癌症疫苗开发的领导者，重点是精准医疗。最近的趋势包括针对特定癌症生物标记的疫苗和个人化癌症免疫疗法的开发。德国强大的研究基础设施以及学术机构和工业界之间的合作正在推动创新并推动新癌症疫苗的临床试验。
• 印度：在印度，癌症疫苗市场正在不断发展，重点是提供负担得起且易于获得的解决方案。最近的进展包括针对子宫颈癌和其他高负担癌症推出具有成本效益的疫苗。印度不断增强的研究能力和官民合作关係正在加强疫苗的开发和分配，并满足该地区对预防性癌症疫苗的需求。
• 日本：日本在癌症疫苗研究方面正在取得突破，着重于先进技术与精准医疗的融合。最近的发展包括针对特定癌症的几种创新候选疫苗的进展以及 mRNA 和基于载体的疫苗等尖端平台的使用。日本对研究和发展的承诺正在推动癌症疫苗治疗的进步。

常问问题

Q.1 癌症疫苗的市场规模有多大？

A1. 到 2030 年，全球癌症疫苗市场预计将达到 155 亿美元。

Q.2 癌症疫苗市场的成长预测如何？

A2. 2024年至2030年，全球癌症疫苗市场预计将以10.5%的复合年增长率成长。

Q.3 影响癌症疫苗市场成长的关键驱动因素有哪些？

A3. 该市场的主要驱动力是对更有效、侵入性更小的癌症治疗的需求不断增长、人们对癌症疫苗益处的认识不断提高以及政府对促进癌症疫苗接种的支持。

Q4.市场的主要细分市场是：

A4. 癌症疫苗市场前景广阔，医院和政府供应管道充满机会。

Q5.市场的主要企业是：

A5. 主要癌症疫苗公司如下：

• Merck
• GSK
• Dendreon Pharmaceuticals
• Dynavax Technologies
• Ferring
• Amgen
• Moderna
• Sanofi
• AstraZeneca
• Bristol-Myers Squibb

Q6.未来最大的细分市场是什么？

A6.预防癌症的预防性疫苗预计将在预测期内达到最高成长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 由于癌症患者数量的增加和完善的医疗保健系统，预计北美在预测期内将出现最高的增长。

Q8. 可以客製化报告吗？

A8. 是的，我们提供 10% 的客製化服务，无需额外费用。

目录

第一章执行摘要

第二章全球癌症疫苗市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球癌症疫苗市场趋势（2018-2023）与预测（2024-2030）
• 全球癌症疫苗市场：依疫苗类型
  • 预防
  • 治疗性的
• 全球癌症疫苗市场：依技术分类
  • 重组
  • 全细胞
  • 病毒载体
  • DNA癌症疫苗
• 全球癌症疫苗市场：按分销管道划分
  • 医院
  • 政府供应

第四章市场趋势与预测分析：按地区划分，2018-2030

• 全球癌症疫苗市场：按地区
• 北美癌症疫苗市场
• 欧洲癌症疫苗市场
• 亚太地区癌症疫苗市场
• 其他地区癌症疫苗市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 按疫苗类型
  • 依技术
  • 按分销管道
  • 按地区
• 全球癌症疫苗市场新趋势
• 战略分析
  • 新产品开发
  • 扩大全球癌症疫苗市场产能
  • 全球癌症疫苗市场的併购和合资企业
  • 认证和许可

第七章主要企业概况

• Merck
• GSK
• Dendreon Pharmaceuticals
• Dynavax Technologies
• Ferring
• Amgen
• Moderna
• Sanofi
• AstraZeneca
• Bristol-Myers Squibb

Cancer Vaccine Trends and Forecast

The future of the global cancer vaccine market looks promising with opportunities in the hospital and government supplier channels. The global cancer vaccine market is expected to reach an estimated $15.5 billion by 2030 with a CAGR of 10.5% from 2024 to 2030. The major drivers for this market are rising demand for more effective and less invasive cancer treatment, growing awareness of the benefits of cancer vaccines, and supportive government initiatives to promote cancer vaccination.

• Lucintel forecasts that preventive is expected to witness highest growth over the forecast period due to its ability to prevent cancer from developing in the first place.
• Within this market, hospital is expected to witness higher growth over the forecast period due to the increasing number of individuals seeking cancer diagnosis and treatment in hospitals.
• North America is expected to witness highest growth over the forecast period due to the rising number of cancer patients and presence of well-established healthcare system in the region.

Emerging Trends in the Cancer Vaccine Market

Emerging trends in the cancer vaccine market are shaping the future of cancer treatment and prevention. These trends highlight advancements in technology, personalized medicine, and market dynamics influencing vaccine development and adoption.

• Advancement of mRNA Technology: The use of mRNA technology in cancer vaccines is a major trend, driven by its success in COVID-19 vaccines. mRNA vaccines are being developed for various cancers, offering the potential for personalized treatment and targeted immune responses, leading to innovative and effective cancer therapies.
• Personalized Cancer Vaccines: Personalized cancer vaccines, tailored to an individual's unique cancer profile, are gaining traction. These vaccines aim to stimulate the immune system to target specific tumor antigens, improving efficacy and reducing side effects, which represents a shift towards more customized and effective cancer treatments.
• Integration of Artificial Intelligence: Artificial Intelligence (AI) is increasingly being integrated into cancer vaccine development. AI algorithms are used to identify potential cancer targets, optimize vaccine designs, and analyze clinical trial data, accelerating the development process and enhancing the precision of vaccine therapies.
• Increased Investment in Immuno-Oncology: There is a growing investment in immuno-oncology, focusing on developing vaccines that harness the body's immune system to fight cancer. This trend is driven by the potential for breakthrough therapies and the growing understanding of immune system mechanisms in cancer treatment.
• Global Collaborations and Partnerships: Increased global collaborations and partnerships between biotech companies, academic institutions, and research organizations are enhancing the development of cancer vaccines. These collaborations facilitate the sharing of knowledge, resources, and technologies, leading to accelerated progress and innovation in vaccine research.

Emerging trends such as the advancement of mRNA technology, personalized cancer vaccines, integration of AI, increased investment in immuno-oncology, and global collaborations are reshaping the cancer vaccine market. These trends drive innovation, enhance precision, and improve treatment outcomes, leading to more effective and personalized cancer therapies.

Recent Developments in the Cancer Vaccine Market

Recent developments in the cancer vaccine market reflect significant progress in research, technology, and regulatory support. These developments are driving advancements in vaccine efficacy, personalization, and accessibility.

• Development of mRNA-Based Cancer Vaccines: The development of mRNA-based cancer vaccines represents a major advancement. These vaccines leverage the mRNA platform to encode cancer-specific antigens, triggering targeted immune responses. Success in early trials and the application of mRNA technology from COVID-19 vaccines are accelerating progress in this area.
• Approval of New Therapeutic Vaccines: The approval of new therapeutic cancer vaccines has expanded treatment options. Recent approvals by regulatory agencies for vaccines targeting melanoma, prostate cancer, and other types are paving the way for innovative therapies and broader clinical use.
• Expansion of Clinical Trials: There has been a significant expansion in clinical trials for cancer vaccines, with increased participation in global studies. This expansion allows for more comprehensive testing of vaccine efficacy and safety, facilitating the development of new and improved vaccines for various cancers.
• Emergence of Combination Therapies: The use of combination therapies, integrating cancer vaccines with other treatments such as checkpoint inhibitors or targeted therapies, is a notable development. Combining vaccines with other modalities enhances treatment efficacy and offers new approaches to managing complex cancers.
• Focus on Global Access and Affordability: Efforts to improve global access and affordability of cancer vaccines are gaining momentum. Initiatives to reduce production costs and increase vaccine availability in low- and middle-income countries are addressing disparities and enhancing global cancer prevention efforts.

Recent developments such as the advancement of mRNA-based vaccines, approval of new therapeutic vaccines, expansion of clinical trials, emergence of combination therapies, and focus on global access are significantly impacting the cancer vaccine market. These developments drive innovation, improve treatment options, and enhance accessibility in cancer care.

Strategic Growth Opportunities for Cancer Vaccine Market

Strategic growth opportunities in the cancer vaccine market are emerging across various applications, driven by advancements in technology, research, and global healthcare needs. These opportunities present avenues for expanding market reach and enhancing therapeutic options.

• Expansion of Personalized Vaccines: Expanding the development of personalized cancer vaccines presents a significant growth opportunity. By tailoring vaccines to individual patient profiles and tumor characteristics, this approach offers the potential for more effective treatments and improved patient outcomes.
• Advancement in mRNA and DNA Vaccine Technologies: Advancements in mRNA and DNA vaccine technologies create growth opportunities by providing innovative platforms for developing targeted cancer therapies. These technologies enable the creation of vaccines that specifically target cancer cells, offering new treatment possibilities.
• Integration of Combination Therapies: Integrating cancer vaccines with other therapeutic modalities, such as immune checkpoint inhibitors or targeted therapies, offers a growth opportunity. Combination therapies can enhance treatment efficacy and address diverse cancer types, leading to improved patient outcomes and market potential.
• Focus on Global Market Penetration: Expanding market penetration in emerging regions, such as Asia-Pacific and Latin America, offers growth opportunities. By addressing local healthcare needs and increasing vaccine accessibility, companies can tap into new markets and enhance global reach.
• Investment in Collaborative Research: Investing in collaborative research and partnerships with academic institutions and biotechnology firms provides growth opportunities. These collaborations facilitate the development of cutting-edge vaccine technologies and accelerate the advancement of new cancer treatments.

Strategic growth opportunities in the cancer vaccine market include expansion of personalized vaccines, advancement in mRNA and DNA technologies, integration of combination therapies, focus on global market penetration, and investment in collaborative research. These opportunities drive innovation, enhance treatment options, and expand market reach in cancer care.

Cancer Vaccine Market Driver and Challenges

The cancer vaccine market is influenced by various drivers and challenges, including technological advancements, regulatory factors, and economic considerations. Understanding these factors is essential for navigating the market and fostering growth.

The factors responsible for driving the cancer vaccine market include:

1. Technological Advancements: Technological advancements, such as mRNA and DNA vaccine platforms, drive market growth by enabling the development of targeted and personalized cancer therapies. These innovations improve vaccine efficacy and expand treatment options.

2. Increased Investment in Research: Increased investment in cancer vaccine research supports the development of new and effective vaccines. Funding from government agencies, private investors, and pharmaceutical companies accelerates research and enhances vaccine innovation.

3. Growing Awareness and Demand: Growing awareness of cancer prevention and early detection drives demand for cancer vaccines. Public and professional recognition of the benefits of vaccination contributes to increased market adoption and investment.

4. Regulatory Support and Approvals: Regulatory support and streamlined approval processes for innovative cancer vaccines facilitate market entry. Accelerated approvals and supportive regulatory frameworks enable faster development and availability of new treatments.

5. Collaborative Research Initiatives: Collaborative research initiatives between academia, industry, and research organizations drive innovation and progress in cancer vaccine development. Partnerships enhance knowledge sharing, resource allocation, and technology advancement.

Challenges in the cancer vaccine market are:

1. High Development Costs: High development costs associated with cancer vaccine research and clinical trials pose a challenge. Balancing costs with affordability and market potential is crucial for the successful commercialization of new vaccines.

2. Regulatory and Compliance Complexities: Navigating complex regulatory requirements and compliance issues can be challenging. Ensuring adherence to varying regulations across regions adds complexity to vaccine development and market entry.

3. Market Access and Distribution Issues: Market access and distribution challenges, particularly in low- and middle-income countries, impact the availability and affordability of cancer vaccines. Addressing these issues is essential for expanding global reach and improving access.

Major drivers of the cancer vaccine market include technological advancements, increased investment in research, growing awareness and demand, regulatory support, and collaborative research initiatives. Key challenges include high development costs, regulatory complexities, and market access issues. Addressing these factors is vital for fostering growth and innovation in the cancer vaccine market.

List of Cancer Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies cancer vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer vaccine companies profiled in this report include-

• Merck
• GSK
• Dendreon Pharmaceuticals
• Dynavax Technologies
• Ferring
• Amgen
• Moderna
• Sanofi
• AstraZeneca
• Bristol-Myers Squibb

Cancer Vaccine by Segment

The study includes a forecast for the global cancer vaccine by vaccine type, technology, distribution channel, and region.

Cancer Vaccine Market by Vaccine Type [Analysis by Value from 2018 to 2030]:

• Preventive
• Therapeutic

Cancer Vaccine Market by Technology [Analysis by Value from 2018 to 2030]:

• Recombinant
• Whole-Cell
• Viral Vector
• DNA Cancer Vaccines

Cancer Vaccine Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

• Hospitals
• Government Suppliers

Cancer Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Cancer Vaccine Market

Recent advancements in the cancer vaccine market are driven by technological innovations, increasing investment in research, and growing awareness of cancer prevention. Key developments are being observed in the United States, China, Germany, India, and Japan, reflecting each country's focus on improving cancer treatment and prevention strategies through vaccine development.

• United States: In the U.S., the cancer vaccine market is experiencing significant growth with ongoing advancements in personalized and therapeutic vaccines. Recent developments include the progression of mRNA-based vaccines targeting various cancers, such as melanoma and lung cancer. The FDA has accelerated approvals for several innovative cancer vaccines, supporting broader clinical trials and facilitating faster access to novel treatments.
• China: China is rapidly advancing in the cancer vaccine market with increased investment in biotechnology and clinical research. Recent developments include the progress of several domestic cancer vaccines in clinical trials, focusing on therapies for hepatocellular carcinoma and other prevalent cancers. China's supportive regulatory environment and growing research capabilities are driving innovation and accelerating the development of new cancer vaccines.
• Germany: Germany continues to be a leader in cancer vaccine development with a strong emphasis on precision medicine. Recent advancements include the development of vaccines targeting specific cancer biomarkers and personalized cancer immunotherapies. Germany's robust research infrastructure and collaboration between academic institutions and industry are fostering innovation and advancing clinical trials for novel cancer vaccines.
• India: In India, the cancer vaccine market is evolving with a focus on affordable and accessible solutions. Recent developments include the introduction of cost-effective vaccines for cervical cancer and other high-burden cancers. India's growing research capabilities and public-private partnerships are enhancing vaccine development and distribution, addressing the need for preventive cancer vaccines in the region.
• Japan: Japan is making strides in cancer vaccine research with a focus on integrating advanced technologies and precision medicine. Recent developments include the progress of several innovative vaccine candidates targeting specific cancers and the use of cutting-edge platforms like mRNA and vector-based vaccines. Japan's commitment to research and development is driving advancements in cancer vaccine therapies.

Features of the Global Cancer Vaccine Market

Market Size Estimates: Cancer vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer vaccine market size by vaccine type, technology, distribution channel, and region in terms of value ($B).

Regional Analysis: Cancer vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different vaccine types, technologies, distribution channels, and regions for the cancer vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the cancer vaccine market size?

Answer: The global cancer vaccine market is expected to reach an estimated $15.5 billion by 2030.

Q.2 What is the growth forecast for cancer vaccine market?

Answer: The global cancer vaccine market is expected to grow with a CAGR of 10.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the cancer vaccine market?

Answer: The major drivers for this market are rising demand for more effective and less invasive cancer treatment, growing awareness of the benefits of cancer vaccines, and supportive government initiatives to promote cancer vaccination.

Q4. What are the major segments for cancer vaccine market?

Answer: The future of the cancer vaccine market looks promising with opportunities in the hospital and government supplier channels.

Q5. Who are the key cancer vaccine market companies?

Answer: Some of the key cancer vaccine companies are as follows:

• Merck
• GSK
• Dendreon Pharmaceuticals
• Dynavax Technologies
• Ferring
• Amgen
• Moderna
• Sanofi
• AstraZeneca
• Bristol-Myers Squibb

Q6. Which cancer vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that preventive is expected to witness highest growth over the forecast period due to its ability to prevent cancer from developing in the first place.

Q7. In cancer vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the rising number of cancer patients and presence of well-established healthcare system in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cancer vaccine market by vaccine type (preventive and therapeutic), technology (recombinant, whole-cell, viral vector, and DNA cancer vaccines), distribution channel (hospitals and government suppliers), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Cancer Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Cancer Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Cancer Vaccine Market by Vaccine Type
  • 3.3.1: Preventive
  • 3.3.2: Therapeutic
• 3.4: Global Cancer Vaccine Market by Technology
  • 3.4.1: Recombinant
  • 3.4.2: Whole-Cell
  • 3.4.3: Viral Vector
  • 3.4.4: DNA Cancer Vaccines
• 3.5: Global Cancer Vaccine Market by Distribution Channel
  • 3.5.1: Hospitals
  • 3.5.2: Government Suppliers

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Cancer Vaccine Market by Region
• 4.2: North American Cancer Vaccine Market
  • 4.2.1: North American Cancer Vaccine Market by Vaccine Type: Preventive and Therapeutic
  • 4.2.2: North American Cancer Vaccine Market by Distribution Channel: Hospitals and Government Suppliers
• 4.3: European Cancer Vaccine Market
  • 4.3.1: European Cancer Vaccine Market by Vaccine Type: Preventive and Therapeutic
  • 4.3.2: European Cancer Vaccine Market by Distribution Channel: Hospitals and Government Suppliers
• 4.4: APAC Cancer Vaccine Market
  • 4.4.1: APAC Cancer Vaccine Market by Vaccine Type: Preventive and Therapeutic
  • 4.4.2: APAC Cancer Vaccine Market by Distribution Channel: Hospitals and Government Suppliers
• 4.5: ROW Cancer Vaccine Market
  • 4.5.1: ROW Cancer Vaccine Market by Vaccine Type: Preventive and Therapeutic
  • 4.5.2: ROW Cancer Vaccine Market by Distribution Channel: Hospitals and Government Suppliers

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Cancer Vaccine Market by Vaccine Type
  • 6.1.2: Growth Opportunities for the Global Cancer Vaccine Market by Technology
  • 6.1.3: Growth Opportunities for the Global Cancer Vaccine Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global Cancer Vaccine Market by Region
• 6.2: Emerging Trends in the Global Cancer Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Cancer Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Merck
• 7.2: GSK
• 7.3: Dendreon Pharmaceuticals
• 7.4: Dynavax Technologies
• 7.5: Ferring
• 7.6: Amgen
• 7.7: Moderna
• 7.8: Sanofi
• 7.9: AstraZeneca
• 7.10: Bristol-Myers Squibb